Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
Factitious Graves' disease due to biotin immunoassay interference - A case and review of the literature.
The ER membrane-anchored ubiquitin ligase Hrd1 is a positive regulator of T-cell immunity.
Screening for SH3TC2 gene mutations in a series of demyelinating recessive Charcot-Marie-Tooth disease (CMT4).
A Post-stroke Therapeutic Regimen with Omega-3 Polyunsaturated Fatty Acids that Promotes White Matter Integrity and Beneficial Microglial Responses after Cerebral Ischemia.
Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis.
Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.
Current and emerging treatment of multiple sclerosis.
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
Predictors of the 10-year direct costs for treating multiple sclerosis.
Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
Accelerated generation of oligodendrocyte progenitor cells from human induced pluripotent stem cells by forced expression of Sox10 and Olig2.
The influence of coping styles on long-term employment in multiple sclerosis: A prospective study.
Quantitative analysis of multiple sclerosis patients' preferences for drug treatment: a best-worst scaling study.
Quality of life in relapsing-remitting multiple sclerosis patients receiving CinnoVex compared with Avonex.
Schwann cell mitochondria as key regulators in the development and maintenance of peripheral nerve axons.
Evaluation of pulsing magnetic field effects on paresthesia in multiple sclerosis patients, a randomized, double-blind, parallel-group clinical trial.
Imag(in)ing multiple sclerosis: Time to take better pictures.
Interleukin-13 immune gene therapy prevents CNS inflammation and demyelination via alternative activation of microglia and macrophages.
Influenza vaccination in patients with multiple sclerosis is possible with some considerations.
EVASEP: A Noninterventional Study Describing the Perception of Neurologists, Patients, and Caregivers on Caregivers' Role in the Support of Patients Suffering from Multiple Sclerosis Treated with Subcutaneous Interferon Beta 1a.
Comment on Paraparetic Guillain-Barré syndrome: non-demyelinating reversible conduction failure restricted to the lower limbs.
Pathophysiology, assessment and management of multiple sclerosis fatigue: an update.
Tamoxifen: an FDA approved drug with neuroprotective effects for spinal cord injury recovery.
γδ T Cells and NK Cells - Distinct Pathogenic Roles as Innate-Like Immune Cells in CNS Autoimmunity.

Pages